Bridgefront Capital, LLC Vir Biotechnology, Inc. Transaction History
Bridgefront Capital, LLC
- $331 Million
- Q1 2025
A detailed history of Bridgefront Capital, LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Bridgefront Capital, LLC holds 28,205 shares of VIR stock, worth $128,332. This represents 0.05% of its overall portfolio holdings.
Number of Shares
28,205Holding current value
$128,332% of portfolio
0.05%Shares
2 transactions
Others Institutions Holding VIR
# of Institutions
254Shares Held
92.5MCall Options Held
257KPut Options Held
261K-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$75.9 Million0.99% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$74.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$58.3 Million0.0% of portfolio
-
State Street Corp Boston, MA5.73MShares$26.1 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.68MShares$12.2 Million0.0% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $604M
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...